United Imaging Healthcare reported revenue of RMB 10.58 billion during the first nine months of 2026, an increase of 19.43% year over year.
International revenue reached RMB 3.00 billion, increasing 50.30% and accounting for 28.31% of total revenue.
The company reported international expansion across Europe, North America, and Asia-Pacific, including installations of advanced imaging systems.
As of September 30, the company reported 79 U.S. FDA 510(k) clearances, 84 CE certifications, and 170 Chinese NMPA approvals across its portfolio. These figures come from the company's disclosure and have not been independently reconciled against each regulator's device database. PR Newswire
Primary source: United Imaging Healthcare — October 29 Financial Announcement
Why it matters strategically
The results suggest that Chinese medical-device manufacturers are expanding their commercial presence outside their domestic market.
This is particularly relevant to established international manufacturers of MRI, CT, PET/CT, and other advanced imaging systems.
Competition in medical imaging involves more than equipment acquisition prices.
Hospitals evaluate diagnostic performance, reliability, maintenance, software integration, service response times, and total ownership costs.
Consequently, international expansion requires more than obtaining regulatory clearance.
It also requires building local service infrastructure and establishing long-term relationships with healthcare institutions.
